Aeglea BioTherapeutics Inc.

8.04+0.0900+1.13%Vol 33.10K1Y Perf 47.76%
Apr 16th, 2021 09:59 DELAYED
BID7.95 ASK8.15
Open8.12 Previous Close7.95
Pre-Market- After-Market-
 - -%  - -
Target Price
13.00 
Analyst Rating
Strong Buy 1.25
Potential %
63.52 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Market Cap386.05M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
46.82 
Earnings Date
6th May 2021

Today's Price Range

7.828.18

52W Range

5.1011.38

5 Year PE Ratio Range

-2.80-4.40

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
3.11%
1 Month
3.79%
3 Months
-0.38%
6 Months
-2.57%
1 Year
47.76%
3 Years
-11.76%
5 Years
-20.18%
10 Years
-

TickerPriceChg.Chg.%
AGLE8.040.09001.13
AAPL133.63-0.8700-0.65
GOOG2 290.60-6.0600-0.26
MSFT258.90-0.6000-0.23
XOM56.60-0.3800-0.67
WFC42.830.59001.40
JNJ161.070.68000.42
FB305.57-2.2500-0.73
GE13.49-0.0600-0.44
JPM153.541.37000.90
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.29-0.34-17.24
Q03 2020-0.38-0.2923.68
Q02 2020-0.39-0.40-2.56
Q01 2020-0.65-0.5712.31
Q04 2019-0.71-0.658.45
Q03 2019-0.56-0.66-17.86
Q02 2019-0.50-0.55-10.00
Q01 2019-0.50-0.59-18.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.1358.06Positive
6/2021 QR-0.37-12.12Negative
12/2021 FY-1.29-0.78Negative
12/2022 FY-1.0931.88Positive
Next Report Date6th May 2021
Estimated EPS Next Report-0.13
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume33.10K
Shares Outstanding48.02M
Trades Count278
Dollar Volume2.11M
Avg. Volume209.83K
Avg. Weekly Volume76.16K
Avg. Monthly Volume154.95K
Avg. Quarterly Volume210.44K

Aeglea BioTherapeutics Inc. (NASDAQ: AGLE) stock closed at 7.95 per share at the end of the most recent trading day (a 5.3% change compared to the prior day closing price) with a volume of 119.76K shares and market capitalization of 386.05M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 87 people. Aeglea BioTherapeutics Inc. CEO is Anthony G. Quinn.

The one-year performance of Aeglea BioTherapeutics Inc. stock is 47.76%, while year-to-date (YTD) performance is 1.02%. AGLE stock has a five-year performance of -20.18%. Its 52-week range is between 5.1 and 11.38, which gives AGLE stock a 52-week price range ratio of 46.82%

Aeglea BioTherapeutics Inc. currently has a PE ratio of -4.80, a price-to-book (PB) ratio of 2.64, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -66.09%, a ROC of -71.21% and a ROE of -80.93%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Aeglea BioTherapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.13 for the next earnings report. Aeglea BioTherapeutics Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Aeglea BioTherapeutics Inc. is Strong Buy (1.25), with a target price of $13, which is +63.52% compared to the current price. The earnings rating for Aeglea BioTherapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aeglea BioTherapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aeglea BioTherapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 8.23, ATR14 : 0.48, CCI20 : 12.57, Chaikin Money Flow : 0.01, MACD : 0.02, Money Flow Index : 39.09, ROC : 12.29, RSI : 61.34, STOCH (14,3) : 56.60, STOCH RSI : 1.00, UO : 45.25, Williams %R : -43.40), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aeglea BioTherapeutics Inc. in the last 12-months were: Anthony G. Quinn (Buy at a value of $783 750)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (75.00 %)
3 (75.00 %)
2 (100.00 %)
Moderate Buy
1 (25.00 %)
1 (25.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.25
Strong Buy
1.25
Strong Buy
1.00

Aeglea BioTherapeutics Inc.

Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage.

CEO: Anthony G. Quinn

Telephone: +1 512 942-2935

Address: 805 Las Cimas Parkway, Austin 78746, TX, US

Number of employees: 87

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

60%40%

Bearish Bullish

52%48%

Bearish Bullish

61%39%

News

Stocktwits